本维莫德乳膏 | China Drugs ListBenvitimod cream | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 皮肤科Dermatology
- 公开来源记录的适应症
- 本维莫德乳膏(商品名:欣比克,规格:1%(10g:0.1g),持有人:广东中昊药业有限公司)于2019年5月按照化药1类获批上市,适应症:本品用于适合局部治疗的成人轻至中度稳定性寻常型银屑病。 本维莫德乳膏(商品名:泽立美,规格:1%(15g:0.15g),持有人:上海泽德曼医药科技有限公司)于2024年11月按照化药2.4类获批上市,适应症:本品用于2岁及以上轻中度特应性皮炎患者的局部外用治疗。1. Benvitimod cream, Xinbike, 1% (10 g:0.1 g), held by Guangdong Zhonghao Pharmaceutical Co., Ltd.: approved in May 2019 as a China Class 1 chemical medicine for adults with mild-to-moderate stable plaque psoriasis who are suitable for topical therapy. 2. Benvitimod cream, Zelimei, 1% (15 g:0.15 g), held by Shanghai Zedeman Pharmaceutical Technology Co., Ltd.: approved in November 2024 as a China Class 2.4 chemical medicine for topical treatment of mild-to-moderate atopic dermatitis in patients aged 2 years or older.
- 适应症来源与口径
- 来源日期： 2025, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限成人轻至中度稳定性寻常型银屑病的局部治疗。Limited to topical treatment of mild-to-moderate stable plaque psoriasis in adults.
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.